LUMINARI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.371
AS - Asia 13.595
EU - Europa 13.521
SA - Sud America 2.105
Continente sconosciuto - Info sul continente non disponibili 650
AF - Africa 325
OC - Oceania 89
Totale 62.656
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.746
GB - Regno Unito 4.335
CN - Cina 3.509
SG - Singapore 3.475
IT - Italia 2.718
DE - Germania 1.826
HK - Hong Kong 1.784
BR - Brasile 1.585
VN - Vietnam 1.511
SE - Svezia 1.071
BD - Bangladesh 952
FI - Finlandia 796
RU - Federazione Russa 573
FR - Francia 532
UA - Ucraina 527
TR - Turchia 472
KR - Corea 380
CA - Canada 329
IN - India 285
BG - Bulgaria 232
ID - Indonesia 203
AR - Argentina 200
JP - Giappone 180
NL - Olanda 173
MX - Messico 136
IQ - Iraq 125
ES - Italia 109
IE - Irlanda 103
ZA - Sudafrica 90
AE - Emirati Arabi Uniti 89
IL - Israele 85
EC - Ecuador 84
PL - Polonia 83
AU - Australia 80
PK - Pakistan 80
AT - Austria 67
MA - Marocco 67
CO - Colombia 65
CH - Svizzera 53
EG - Egitto 52
SA - Arabia Saudita 47
MY - Malesia 46
VE - Venezuela 44
CL - Cile 43
BE - Belgio 39
PH - Filippine 39
PT - Portogallo 39
LT - Lituania 38
UZ - Uzbekistan 38
TH - Thailandia 35
JO - Giordania 34
CZ - Repubblica Ceca 31
PY - Paraguay 31
IR - Iran 30
KE - Kenya 30
TW - Taiwan 29
RO - Romania 28
NP - Nepal 27
DZ - Algeria 24
BZ - Belize 23
AZ - Azerbaigian 21
CR - Costa Rica 21
DO - Repubblica Dominicana 19
PE - Perù 19
JM - Giamaica 18
BO - Bolivia 17
OM - Oman 16
TN - Tunisia 16
DK - Danimarca 15
AL - Albania 14
HU - Ungheria 14
LB - Libano 14
UY - Uruguay 14
HN - Honduras 13
KG - Kirghizistan 13
KZ - Kazakistan 13
NO - Norvegia 13
SK - Slovacchia (Repubblica Slovacca) 13
BH - Bahrain 12
BY - Bielorussia 11
PA - Panama 11
SV - El Salvador 10
GR - Grecia 9
LV - Lettonia 9
PR - Porto Rico 9
RS - Serbia 9
AM - Armenia 8
GT - Guatemala 8
NI - Nicaragua 8
NZ - Nuova Zelanda 8
HR - Croazia 7
QA - Qatar 7
SI - Slovenia 7
SN - Senegal 7
TT - Trinidad e Tobago 7
EE - Estonia 6
ET - Etiopia 6
GE - Georgia 6
LU - Lussemburgo 6
NG - Nigeria 6
Totale 61.917
Salva come PNG Salva come JPEG
Città #
Ashburn 3.290
Fairfield 3.243
Southend 3.027
Santa Clara 2.722
Singapore 2.146
Woodbridge 1.851
Hong Kong 1.757
Houston 1.465
Chandler 1.210
Seattle 1.192
Wilmington 1.119
San Jose 1.090
Cambridge 1.064
Frankfurt am Main 1.057
Hefei 997
Jacksonville 929
Dearborn 814
Ann Arbor 785
Beijing 717
London 657
Chicago 656
Los Angeles 632
Nyköping 605
Helsinki 583
Council Bluffs 560
Ho Chi Minh City 517
The Dalles 397
New York 384
Hanoi 334
Seoul 320
San Diego 311
Milan 303
Modena 268
Princeton 238
Sofia 225
Salt Lake City 221
Buffalo 220
Dallas 212
Izmir 209
Shanghai 194
Redwood City 193
Eugene 186
São Paulo 178
Lauterbourg 174
Rome 164
Moscow 141
Manchester 140
Jakarta 135
Columbus 109
Munich 104
Elk Grove Village 103
Phoenix 102
Tokyo 100
Bologna 93
Tampa 93
Dublin 92
Toronto 82
Da Nang 75
Bremen 72
Miami 71
Boardman 69
North Bergen 67
Orem 66
Dong Ket 62
Sterling 62
Warsaw 62
Brooklyn 61
Turin 60
Atlanta 59
Falls Church 59
Guangzhou 59
San Francisco 59
Des Moines 58
Yavné 55
Chennai 52
Montreal 52
Rio de Janeiro 52
Haiphong 51
Philadelphia 51
Lancaster 48
Naples 48
Palermo 47
Amsterdam 46
Mexico City 46
Stockholm 46
Denver 44
Istanbul 43
Tappahannock 42
Baghdad 41
Nuremberg 41
Newark 40
Norwalk 39
Dulles 38
Kilburn 38
Miano 38
Kent 36
Turku 36
Redondo Beach 35
Dhaka 34
Florence 34
Totale 42.904
Salva come PNG Salva come JPEG
Nome #
Survival of cancer patients in Italy [La sopravvivenza dei pazienti oncologici in Italia [La sopravvivenza dei pazienti oncologici in Italia] 889
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study 795
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 705
Veno-occlusive disease nurse management: Development of a dynamic monitoring tool by the GITMO nursing group 704
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 635
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 526
T-cell lymphoma in South America and Europe. 514
Il linfoma mantellare 511
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 492
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 476
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 469
Transformed follicular lymphoma 465
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 462
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 443
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 415
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 411
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 410
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 409
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 403
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 381
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 380
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 378
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: Results from the Fondazione Italiana Linfomi MCL-0208 trial 377
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 366
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 358
Prognosis of follicular lymphomas 356
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 348
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 343
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 343
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 342
Pure red-cell aplasia and epoetin therapy 340
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 340
Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma 340
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 337
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 335
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study 334
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 331
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 327
A Gene Expression–based Model to Predict Metabolic Response after Two Courses of ABVD in Hodgkin Lymphoma Patients 323
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 322
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 318
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 317
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 317
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 317
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 316
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 315
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 314
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 312
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 310
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias 310
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients 309
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 309
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 308
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 307
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 307
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 306
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 305
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 305
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 305
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) 304
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy 303
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 303
Bendamustine salvage therapy for T cell neoplasms 299
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma 296
ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial 294
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi Study 294
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi 291
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 290
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 289
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 289
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials 288
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 285
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 283
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 283
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 281
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 280
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 280
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 280
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 278
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 278
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. 276
Advances in Treatment of Follicular Lymphoma 276
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 275
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 275
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 275
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project 273
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients 270
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. 270
Reply to H.J.A. Adams et al and E. Laffon et al 270
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 269
I tumori in Italia. Rapporto 2011: La sopravvivenza dei pazienti oncologici in Italia 268
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi 267
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 267
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 265
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 263
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 263
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials 262
[Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients] 262
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 260
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. 258
Totale 34.774
Salva come PNG Salva come JPEG
Categoria #
all - tutte 247.398
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 247.398
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.342 0 538 521 270 134 271 245 297 471 365 804 426
2022/20233.849 419 393 324 330 460 504 96 396 465 97 220 145
2023/20244.005 113 207 185 229 1.442 205 411 669 78 79 89 298
2024/20259.509 313 88 141 700 1.717 1.465 723 509 1.275 557 929 1.092
2025/202620.606 1.150 893 1.690 2.483 3.003 1.416 2.386 989 1.750 1.695 1.789 1.362
2026/2027930 864 66 0 0 0 0 0 0 0 0 0 0
Totale 62.656